These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 31385441)

  • 41. Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6.
    van Vollenhoven RF; Lee EB; Fallon L; Zwillich SH; Wilkinson B; Chapman D; DeMasi R; Keystone E
    Arthritis Care Res (Hoboken); 2019 Jan; 71(1):71-79. PubMed ID: 29696833
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.
    Lee MY; Park SK; Park SY; Byun JH; Lee SM; Ko SK; Lee EK
    Clin Ther; 2015 Aug; 37(8):1662-76.e2. PubMed ID: 26243076
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis.
    Zhang J; Chen L; Delzell E; Muntner P; Hillegass WB; Safford MM; Millan IY; Crowson CS; Curtis JR
    Ann Rheum Dis; 2014 Jul; 73(7):1301-8. PubMed ID: 24796336
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting.
    Hasvold P; Thuresson M; Sundström J; Hammar N; Kjeldsen SE; Johansson G; Holme I; Bodegård J
    Clin Drug Investig; 2016 Mar; 36(3):225-33. PubMed ID: 26718960
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tofacitinib versus methotrexate in rheumatoid arthritis.
    Lee EB; Fleischmann R; Hall S; Wilkinson B; Bradley JD; Gruben D; Koncz T; Krishnaswami S; Wallenstein GV; Zang C; Zwillich SH; van Vollenhoven RF;
    N Engl J Med; 2014 Jun; 370(25):2377-86. PubMed ID: 24941177
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
    Machado MAÁ; Moura CS; Guerra SF; Curtis JR; Abrahamowicz M; Bernatsky S
    Arthritis Res Ther; 2018 Mar; 20(1):60. PubMed ID: 29566769
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis.
    Kaur K; Kalra S; Kaushal S
    Clin Ther; 2014 Jul; 36(7):1074-86. PubMed ID: 25047498
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Elevated triglyceride levels are associated with increased risk for major adverse cardiovascular events in statin-naïve rheumatoid arthritis patients: A nationwide cohort study.
    Choi W; Kang JH; Park JY; Hong AR; Yoon JH; Kim HK; Kang HC
    Semin Arthritis Rheum; 2023 Dec; 63():152274. PubMed ID: 37844386
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis.
    Winthrop KL; Yamanaka H; Valdez H; Mortensen E; Chew R; Krishnaswami S; Kawabata T; Riese R
    Arthritis Rheumatol; 2014 Oct; 66(10):2675-84. PubMed ID: 24943354
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients With Manifest Arterial Disease.
    van den Berg MJ; van der Graaf Y; de Borst GJ; Kappelle LJ; Nathoe HM; Visseren FLJ;
    Am J Cardiol; 2016 Sep; 118(6):804-810. PubMed ID: 27471056
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
    Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
    Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation.
    Pérez-Román DI; Ortiz-Haro AB; Ruiz-Medrano E; Contreras-Yáñez I; Pascual-Ramos V
    Rheumatol Int; 2018 Apr; 38(4):599-606. PubMed ID: 29264637
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
    Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR
    Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
    Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
    [TBL] [Abstract][Full Text] [Related]  

  • 55. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
    Tanaka Y; Yamaoka K
    Mod Rheumatol; 2013 May; 23(3):415-24. PubMed ID: 23212593
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.
    Takeuchi T; Yamanaka H; Yamaoka K; Arai S; Toyoizumi S; DeMasi R; Fukuma Y; Hirose T; Sugiyama N; Zwillich SH; Tanaka Y
    Mod Rheumatol; 2019 Sep; 29(5):756-766. PubMed ID: 30489177
    [No Abstract]   [Full Text] [Related]  

  • 57. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist.
    Charles-Schoeman C; Gonzalez-Gay MA; Kaplan I; Boy M; Geier J; Luo Z; Zuckerman A; Riese R
    Semin Arthritis Rheum; 2016 Aug; 46(1):71-80. PubMed ID: 27079757
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
    van Vollenhoven RF; Fleischmann R; Cohen S; Lee EB; García Meijide JA; Wagner S; Forejtova S; Zwillich SH; Gruben D; Koncz T; Wallenstein GV; Krishnaswami S; Bradley JD; Wilkinson B;
    N Engl J Med; 2012 Aug; 367(6):508-19. PubMed ID: 22873531
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Herpes Zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan.
    Chen YJ; Chen YM; Huang WN; Chen HH; Liao TL; Chen JP; Hsieh TY; Chen YH; Chen DY
    Medicine (Baltimore); 2020 Oct; 99(41):e22504. PubMed ID: 33031288
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data.
    Burmester GR; Curtis JR; Yun H; FitzGerald O; Winthrop KL; Azevedo VF; Rigby WFC; Kanik KS; Wang C; Biswas P; Jones T; Palmetto N; Hendrikx T; Menon S; Rojo R
    Drug Saf; 2020 Apr; 43(4):379-392. PubMed ID: 32006348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.